Clinical trials: In Stent Restenosis
Coronary Artery Disease, Coronary Artery Stenosis
Pharmacokinetics of Everolimus in Absorb BVS in Patients With Coronary Artery Lesions
The ABSORB III PK sub-study is a prospective, open-label, non-blinded study enrolling approximately 12 subjects in up to 5 US sites. ABSORB III PK sub-study is a part of ABSORB III RCT (NCT01751906).
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Trial name
- NCT02229864
- Testing
- Coronary artery stenting: Absorb BVS
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Abbott Medical Devices
Coronary Stenosis
FrActional Flow Reserve Guided Drug Coated Balloon Only Strategy in De Novo coronarY Lesions (FADDY)
Drug-eluting stent (DES) has been the primary choice for in suit coronary lesions treatment. In comparison to bare-metal stent (BMS), it evidently decreases the rate of restenosis.
- Trial name
- FADDY (NCT03452904)
- Testing
- Drug-coated balloon, Drug-eluting stent
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Peripheral Vascular Disease
GORE VIABAHN® Versus Plain Old Balloon Angioplasty (POBA) for Superficial Femoral Artery (SFA) In-Stent Restenosis
This is a prospective, randomized, multi-center study recruiting patients with an in-stent restenosis in the superficial femoral artery. The safety and efficacity of the Viabahn endoprosthesis (W.L.
- Trial name
- RELINE (NCT01108861)
- Testing
- GORE VIABAHN® Endoprosthesis, Plain old balloon angioplasty
- Where
- 6 sites in Belgium, Germany
- Volunteers
- 100 people
- Sponsor
- Flanders Medical Research Program
In-Stent Coronary Artery Restenosis
REWARDS- In-stent Restenosis
To define the long-term incidence and frequency of ISR follow DES implantation. Compare the clinical presentation, treatment and intervention success among de novo coronary artery stenosis and DES ISR.
- Trial name
- NCT03008772
- Where
- United States
- Sponsor
- Medstar Health Research Institute
Peripheral Arterial Disease
Drug Eluting Balloon in Peripheral Intervention for In-Stent Restenosis
The purpose of this study is to evaluate the efficacy of drug-eluting balloon angioplasty followed versus conventional balloon angioplasty in superficial femoral artery and popliteal artery re-stenosis.
- Trial name
- DEBATE-ISR (NCT01558531)
- Testing
- DEB, POBA
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Leonardo Bolognese, MD
Coronary Artery Disease, Angina Pectoris
DUrable Polymer-based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity
Rationale: The introduction of drug-eluting stents (DES) in the treatment of coronary artery disease has led to a significant reduction in morbidity but there are further demands on DES performance.
- Conditions
- Coronary Artery Disease, Angina Pectoris, Unstable Angina Pectoris, Acute Coronary Syndrome
- Trial name
- DUTCHPEERS (NCT02175706)
- Testing
- Resolute Integrity®, Promus Element®
- Where
- 4 sites in Netherlands
- Volunteers
- 1,811 people
- Sponsor
- Thorax Centrum Twente
Peripheral Arterial Disease
STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR)
Cohort 1: Single-Arm, multicenter study to continue to assess the safety and performance of the Stellarex 035 Drug Coated Balloon (formerly known as the Cardiovascular Ingenuity (CVI) Paclitaxel-Coated PTA Balloon Catheter) in…
- Trial name
- ILLUMENATE (NCT01927068)
- Testing
- Stellarex 0.035" Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB)
- Where
- 44 sites in Australia, Austria and 8 more
- Volunteers
- 499 people
- Sponsor
- Spectranetics Corporation
Acute Coronary Syndrome
Comparison of Stent Graft, Sirolimus Stent, and Bare Metal Stent Implanted in Patients With Acute Coronary Syndrome
During the 6-month period 119 patients with acute coronary syndrome, were randomized to either stent graft group (n=40), sirolimus eluting stent group (n=39), or bare metal stent group (n=40).
- Trial name
- NCT00452517
- Testing
- Percutaneous Coronary Intervention
- Where
- Croatia
- Volunteers
- 100 people
- Sponsor
- University of Zagreb
In-Stent Restenosis, Cardiovascular Diseases
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Superiority Trial to Evaluate the Safety and Efficacy of the MagicTouch™ Sirolimus- Coated Balloon in the Treatment of Coronary Drug-Eluting Stent In-Stent Restenosis.
- Conditions
- In-Stent Restenosis, Cardiovascular Diseases, Coronary Artery Disease
- Trial name
- MAGICAL ISR (NCT05908331)
- Testing
- Sirolimus Drug Coated Balloon, Plan balloon Angioplasty (POBA)
- Where
- 28 sites in United States
- Volunteers
- 492 people
- Sponsor
- Concept Medical Inc.
Coronary Stenosis, Coronary Artery Stenosis
A Study to EXhibit Percutaneous Coronary Artery Dilatation With Non-Slip Element Balloon
The objective of this study is to evaluate safety and effectiveness of the Lacrosse NSE ALPHA coronary dilatation catheter during PCI in subjects with stenotic coronary arteries.
- Conditions
- Coronary Stenosis, Coronary Artery Stenosis, In-stent Restenosis
- Trial name
- EXPANSE-PTCA (NCT04985773)
- Testing
- Lacrosse NSE ALPHA coronary dilatation catheter
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Infraredx
In-stent Restenosis
Anti-inflammatory Therapy for Recurrent In-stent Restenosis
This study is aimed at making a comparison of the safety and efficacy of standard drug therapy (control group), standard drugs combined with lose-dose colchicine therapy (colchicine group) and standard drug combined with…
- Trial name
- NCT06090890
- Testing
- Colchicine, Prednisone, Aspirin
- Where
- 4 sites in China
- Volunteers
- 252 people
- Sponsor
- Fu Wai Hospital, Beijing, China
Mesenteric Ischemia, Bowel; Ischemic
Copenhagen Mesenteric Stent Study - A Randomized Trial of Stent Versus Covered Stent Treatment for Chronic Mesenteric Ischemia
Chronic mesenteric ischemia (CMI) is often caused by narrowings in the arteries providing blood to the intestines. Endovascular stent placement is considered the preferred treatment for this condition.
- Conditions
- Mesenteric Ischemia, Bowel; Ischemic, Superior Mesenteric Atherosclerosis, Mesenteric Artery Stenosis
- Trial name
- COMESS (NCT05244629)
- Testing
- BMS vs. CS
- Where
- Denmark
- Volunteers
- 98 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Peripheral Arterial Disease
TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions
A retrospective study to evaluate Turbo Power laser atherectomy + drug coated balloon (DCB) angioplasty for the treatment of femoropopliteal de novo/restenotic lesions and in-stent restenosis (ISR).
- Trial name
- NCT03306199
- Testing
- Laser Atherectomy
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Spectranetics Corporation
Coronary Artery Disease, Restenoses, Coronary
Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5
The hypothesis of the study is, that there is a significant interaction in treatment effect between the OCT pattern of neointima (heterogeneous or homogeneous) and the type of percutaneous coronary intervention (drug-eluting…
- Trial name
- ISAR-DESIRE5 (NCT05544864)
- Testing
- Drug eluting stent (DES), Drug coated ballloon (DCB)
- Where
- 5 sites in Germany, Spain
- Volunteers
- 376 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Disease, Coronary Artery Disease
EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease
The purpose of this two part study is the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of the specific setting of patients with Multi-Vessel Coronary…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis
- Trial name
- EXecutive (NCT00531011)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent System, TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System
- Where
- 24 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Abbott Medical Devices
Stenosis, Restenosis
Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft
The objective of this study is to assess the safety and effectiveness of the COVERA™ Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the Arteriovenous (AV) access circuit.
- Trial name
- AVeNEW (NCT02649946)
- Testing
- Covera Vascular Covered Stent following PTA, Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon
- Where
- 24 sites in United States, Australia and 6 more
- Volunteers
- 280 people
- Sponsor
- C. R. Bard
Stent Restenosis, Intimal Hyperplasia
Self-expanding Nitinol Stents of High vs. Low Chronic Outward Force in De-novo Femoropopliteal Occlusive Arterial Lesions
The objective of the BIOFLEX-COF trial is to investigate differences in formation of intimal hyperplasia at one and two years after implantation of nitinol-stents with high vs.
- Trial name
- BIOFLEX-COF (NCT03097679)
- Testing
- Pulsar Stent, LifeStent Flexstar Vascular Stent
- Where
- Austria
- Volunteers
- 86 people
- Sponsor
- Medical University of Vienna
Metal Allergy, Contact Allergy
Metal Allergy In-Stent Restenosis Study
In-stent restenosis remains one of the most challenging problems in patients after coronary artery angioplasty. Angiographically, it is discovered in 10% of the patients after drug-eluting stent (DES) implantation.
- Conditions
- Metal Allergy, Contact Allergy, Restenoses, Coronary, In-stent Restenosis
- Trial name
- RESTALL (NCT03588962)
- Testing
- In-stent restenosis
- Volunteers
- 1,000 people
- Sponsor
- Silesian Centre for Heart Diseases
Patients Above 18 Years
Below Study - Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the Knee
The Below-Study is a randomized, prospective mono-centre trial on the efficacy and safety the adjunctive use of a GP IIb/IIIa antagonist for prevention of early reocclusion in arterial below-the knee interventions.
- Trial name
- NCT00163254
- Testing
- abciximab, stent and drug eluting stent
- Where
- Germany
- Sponsor
- University Hospital Tuebingen
Peripheral Arterial Disease
Outcomes of Endovascular Treatment of Superficial Femoral Artery In-stent Restenosis
Lower limb peripheral arterial disease (PAD) is a common, important manifestation of systemic atherosclerosis. Stenosis or occlusions in the superficial femoral artery (SFA) may result in intermittent claudication or even…
- Trial name
- NCT04123639
- Testing
- PTA
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assiut University